Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000725017 | SCV000333264 | uncertain significance | not provided | 2015-07-31 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000331844 | SCV000517038 | likely benign | not specified | 2016-03-03 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Labcorp Genetics |
RCV001085032 | SCV001006546 | benign | Neuronal ceroid lipofuscinosis | 2023-12-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002365298 | SCV002659132 | likely benign | Inborn genetic diseases | 2018-01-22 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Natera, |
RCV001085032 | SCV001454742 | uncertain significance | Neuronal ceroid lipofuscinosis | 2020-01-24 | no assertion criteria provided | clinical testing |